Moderna Surges on Cancer Vaccine; Estee Lauder Rallies on Earnings | Stock Movers

Moderna shares surged 101%, the biotech’s biggest intraday gain on record, after the company and partner Merck & Co. reported results from a large, late-stage trial of a personalized cancer vaccine combined with Keytruda. The treatment helped reduce melanoma recurrence, according to a statement issued Wednesday. The study also met a key secondary goal, showing the vaccine could help prevent tumors from spreading to new areas of the body. The results supplied a major catalyst for Moderna, with investors responding to late-stage evidence supporting the potential of personalized cancer treatment alongside Keytruda. Estee Lauder shares rallied after the beauty company reported fourth-quarter adjusted earnings per share and sales metrics above consensus expectations. The midpoint of its fiscal 2027 organic sales guidance range and adjusted EPS guidance range also exceeded Street views. The available information does not provide the reported figures or guidance amounts, but the combination of quarterly outperformance and an outlook above expectations supported the stock. La-Z-Boy shares tumbled at the open after the furniture maker’s second-quarter sales forecast missed the average analyst estimate. The company’s outlook contrasted with the favorable clinical data and earnings-related developments driving Moderna and Estee Lauder. The moves highlight how late-stage trial results, quarterly performance and forward guidance can produce sharply different outcomes across sectors. Moderna’s data generated the session’s largest reaction, Estee Lauder benefited from both results and forecasts above expectations, and La-Z-Boy faced pressure from weaker-than-expected sales guidance.